Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
D001479:Basal Ganglia / Q000378:metabolism / Q000473:pathology; D002262:Carboxy-Lyases / Q000378:metabolism; D002531:Cerebellum / Q000473:pathology; D002540:Cerebral Cortex / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects; D004027:Diencephalon / Q000473:pathology; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005260:Female; D005971:Glutamates; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008875:Middle Aged; D009410:Nerve Degeneration / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012701:Serotonin / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects*; D013788:Thalamus / Q000378:metabolism
D005971:Glutamates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004296:Dopa Decarboxylase; D004298:Dopamine; D006719:Homovanillic Acid